Non-canonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity

Publication alert! If you are into myeloid neoplasms, whether it be a physician struggling to pick the best treatment or a translational researcher curious about stem cells, this review is for you! (and everyone else). Check it out online first @CCR_AACR:

Wow — top line VERONA results are negative — no advantage to AZA + VEN compared to AZA alone for higher-risk #MDSsm. AZA or DAC alone remain the standard for HR-MDS. So disappointing😢 🎗️🩸 https://t.co/vek9GIMKwo

President Donald Trump’s administration appears to be killing much, if not all, of a historic initiative that was the first, and is still the largest, National Institutes of Health effort centered on the health needs of women.

Just out!! Our work on NK cells dysfunction in patients with clonal cytopenias frequently preceding MDS is finally published in @NatureComms! This was a collab between the #collalab and @may_daher @MDAndersonNews 👉

XV Reunión Anual @gesmd y VI Curso Educacional en #SMD 👉🏻 #gesmd2025 Un encuentro con un nivel científico excepcional en el que más de 200 expertos abordan en Madrid los desafíos del #sindromemielodisplasico. 👏🏻 Enhorabuena a las coordinadoras, Patricia Font y Mar Tormo y a

#gesmd2025 👉🏻 @josejfuster, de @CNIC_CARDIO, realiza una excelente discusión sobre CHIP Y #CARDIOLOGÍA. #SMD #HematoEnRed @sehh_es

The US government is sistematically erasing bios of women in STEM from the websites of gubernamental agencies such as NASA or NIH. Some amazing 😍 people started this website to prevent those women's stories to be forgotten. Please check it out and share!

La familia de Hemato-Oncología representando a @ClinicaNavarra y @CIMA_unav en #Hemato2024 @sehh_es 👩🏻‍🔬🔬🧪💻 Hasta el año que viene!

That was a very emotional moment. Congrats!

Full house today at #Hemato2024 @sehh_es listening to @garciamanero

Delighted to see Dr. @TeresaEzponda delivering a talk about resistance to HMAs in MDS @sehh_es #Hemato2024 👩🏻‍🔬

We're hiring! Looking for highly motivated PhD candidates to join the lab this fall. Spread the word! https://t.co/5umaDVzHg7 #joboffer #phd #predoctoralcandidate #fundedposition @CIMA_unav @unav @SEHHJoven @precarios

T-cell dysfunctions in myelodysplastic syndromes https://t.co/vYKZdTeNAg #hematopoiesisandstemcells #immunobiologyandimmunotherapy #myeloidneoplasia

I am really pleased to share our latest manuscript, just published @Nature! You can access the manuscript (open access) here: https://t.co/qVDuJDz61s Special thanks to Maria Carolina Florian for the great commentary:

While we need to work toward identifying novel therapeutic targets that eliminate granulomono-biased #HSC (aka LMPP), our findings provide a rationale for the genetic or phenotypic monitoring of #venetoclax treated patients to identify those at higher risk of resistance/relapse.

We now show that, in patients with "primitive" hierarchies with underlying #HSC clones harboring mutations in RUNX1 or STAG2, #venetoclax therapy induces selective pressure toward the expansion of those clones, rewiring the #MDSsm hematopoietic trajectory and driving relapse.

Specifically, patients with #HSC trajectories sustained by long-term/primitive #MDSsm stem cells are more sensitive to #venetoclax, as opposed to patients with granulomono-biased trajectories, sustained by LMPPs. The latter are associated with driver mutations in RUNX1 and STAG2

We previously reported that hematopoietic trajectories driven by #HSC in distinct differentiation states maintain #MDSsm, expand at disease progression to HR-MDS/sAML, and rely on different oncogenic pathways to survive.

Just out in @NatureComms, our follow up study on the relevance of #HSC hierarchies in #venetoclax sensitivity by #MDSsm patients. #collalab @MDAndersonNews 🧵 below: